(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel’s 'Stonehenge’ not alone with near 30 similar sites, satellite imagery reveals - 2Manhunt for Brown University shooter continues: FBI releases photos of suspect, announces $50K reward
- 3Excited visitors for NASA's moon launch jockey for prime views
- 4'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- 5Vote In favor of Your Favored Sort Of Bevarage
- Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
- Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- Vote In favor of Your Favored Kind Of Vegetable
- IDF, police arrest eleven for criminal, terror-related activity over weekend
- Find the Insider facts of Compelling Systems administration: Building Associations for Progress
- FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- Manual for Famous people Known for Their Altruistic Endeavors
- The Best Games On the planet
- Misjudged Objections For Solo Voyagers
